Table 2 Physical function and health-related quality of life through week 100/112
Patients < 65 years | Patients ≥ 65 years | |||
|---|---|---|---|---|
Placebo + MTX ➔ Golimumab + MTX (n = 179) | Golimumab + MTX (n = 336) | Placebo + MTX ➔ Golimumab + MTX (n = 18) | Golimumab + MTX (n = 59) | |
Improvement from baseline in HAQ-DI | ||||
Week 14 | 0.20 ± 0.57 | 0.50 ± 0.56*** | 0.10 ± 0.35 | 0.50 ± 0.65* |
Week 24 | 0.22 ± 0.56 | 0.53 ± 0.62*** | 0.07 ± 0.43 | 0.53 ± 0.71** |
Week 52 | 0.45 ± 0.60 | 0.53 ± 0.65 | 0.11 ± 0.41 | 0.40 ± 0.63 |
Week 100 | 0.49 ± 0.63 | 0.55 ± 0.67 | 0.29 ± 0.56 | 0.44 ± 0.60 |
Mean change from baseline in SF-36 PCS | ||||
Week 12 | 3.3 ± 7.4 | 5.9 ± 7.5*** | 2.1 ± 7.3 | 6.0 ± 8.7 |
Week 24 | 4.0 ± 7.2 | 8.2 ± 8.2*** | 2.3 ± 8.6 | 8.9 ± 8.9** |
Week 52 | 7.1 ± 8.0 | 8.2 ± 8.8 | 4.4 ± 8.7 | 7.4 ± 8.9 |
Week 112 | 7.2 ± 8.7 | 7.7 ± 9.0 | 5.7 ± 6.3 | 6.8 ± 10.1 |
Mean change from baseline in SF-36 MCS | ||||
Week 12 | 1.6 ± 10.2 | 5.3 ± 10.0*** | 0.02 ± 5.80 | 2.9 ± 11.5 |
Week 24 | 1.2 ± 10.3 | 7.1 ± 10.2*** | 1.7 ± 7.6 | 6.0 ± 10.7 |
Week 52 | 4.1 ± 11.4 | 7.1 ± 11.0 | 2.0 ± 9.2 | 5.8 ± 12.2 |
Week 112 | 3.9 ± 11.5 | 6.0 ± 11.3 | 1.7 ± 9.2 | 4.4 ± 10.7 |